RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL)
Data Presented at the American Society of Hematology (ASH) 2021 Annual Meeting Demonstrated AlloCAR T™ Could be Safe and Effective in Producing Durable Responses
In the ALPHA Trials with ALLO-501 and ALLO-501A, Treatment was Initiated Approximately 2 Days from Enrollment, Eliminating Any Need for Bridging Therapy
Company Intends to Initiate a Phase 2 Pivotal Trial in Mid-2022
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.